- Home
- EVOK vs ALLR Comparison
EVOK vs ALLR Comparison
Compare EVOK & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- ALLR
- Stock Information
- Founded
- EVOK 2007
- ALLR 2004
- Country
- EVOK United States
- ALLR United States
- Employees
- EVOK N/A
- ALLR N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- ALLR Health Care
- Exchange
- EVOK Nasdaq
- ALLR Nasdaq
- Market Cap
- EVOK 5.4M
- ALLR 15.8M
- IPO Year
- EVOK 2013
- ALLR N/A
- Fundamental
- Price
- EVOK $5.53
- ALLR $0.94
- Analyst Decision
- EVOK
- ALLR Strong Buy
- Analyst Count
- EVOK 0
- ALLR 1
- Target Price
- EVOK N/A
- ALLR $9.00
- AVG Volume (30 Days)
- EVOK 476.4K
- ALLR 367.8K
- Earning Date
- EVOK 08-14-2025
- ALLR 08-15-2025
- Dividend Yield
- EVOK N/A
- ALLR N/A
- EPS Growth
- EVOK N/A
- ALLR N/A
- EPS
- EVOK N/A
- ALLR N/A
- Revenue
- EVOK $12,794,859.00
- ALLR N/A
- Revenue This Year
- EVOK $57.82
- ALLR N/A
- Revenue Next Year
- EVOK $59.12
- ALLR N/A
- P/E Ratio
- EVOK N/A
- ALLR N/A
- Revenue Growth
- EVOK 70.02
- ALLR N/A
- 52 Week Low
- EVOK $1.94
- ALLR $0.61
- 52 Week High
- EVOK $12.32
- ALLR $6.00
- Technical
- Relative Strength Index (RSI)
- EVOK 54.74
- ALLR 47.03
- Support Level
- EVOK $4.61
- ALLR $0.85
- Resistance Level
- EVOK $7.04
- ALLR $1.01
- Average True Range (ATR)
- EVOK 0.49
- ALLR 0.05
- MACD
- EVOK 0.03
- ALLR -0.01
- Stochastic Oscillator
- EVOK 37.86
- ALLR 47.55
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.